ACELYRIN, INC Financials
| SLRN Stock | USD 4.55 0.02 0.44% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.05 | 8.6501 |
|
|
The essential information of the day-to-day investment outlook for ACELYRIN, INC includes many different criteria found on its balance sheet. An individual investor should monitor ACELYRIN, INC's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in ACELYRIN, INC.
Net Income |
|
ACELYRIN, |
Understanding current and past ACELYRIN, INC Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of ACELYRIN, INC's financial statements are interrelated, with each one affecting the others. For example, an increase in ACELYRIN, INC's assets may result in an increase in income on the income statement.
ACELYRIN, INC Stock Summary
ACELYRIN, INC competes with Tff Pharmaceuticals, Eliem Therapeutics, Inhibrx, and Enliven Therapeutics. ACELYRIN, INC is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 00445A100 |
| Location | California; U.S.A |
| Business Address | 4149 Liberty Canyon |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.acelyrin.com |
| Phone | 805 730 0360 |
| Currency | USD - US Dollar |
ACELYRIN, INC Key Financial Ratios
| Return On Equity | -0.42 | ||||
| EBITDA | (381.53 M) | ||||
| Net Income | (381.64 M) | ||||
| Book Value Per Share | 5.29 X | ||||
| Market Capitalization | 458.49 M |
ACELYRIN, Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ACELYRIN, INC's current stock value. Our valuation model uses many indicators to compare ACELYRIN, INC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ACELYRIN, INC competition to find correlations between indicators driving ACELYRIN, INC's intrinsic value. More Info.ACELYRIN, INC Common is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers . At this time, ACELYRIN, INC's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ACELYRIN, INC's earnings, one of the primary drivers of an investment's value.ACELYRIN, INC Common Systematic Risk
ACELYRIN, INC's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ACELYRIN, INC volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on ACELYRIN, INC Common correlated with the market. If Beta is less than 0 ACELYRIN, INC generally moves in the opposite direction as compared to the market. If ACELYRIN, INC Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ACELYRIN, INC Common is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ACELYRIN, INC is generally in the same direction as the market. If Beta > 1 ACELYRIN, INC moves generally in the same direction as, but more than the movement of the benchmark.
ACELYRIN, INC December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of ACELYRIN, INC help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ACELYRIN, INC Common. We use our internally-developed statistical techniques to arrive at the intrinsic value of ACELYRIN, INC Common based on widely used predictive technical indicators. In general, we focus on analyzing ACELYRIN, Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ACELYRIN, INC's daily price indicators and compare them against related drivers.
| Downside Deviation | 5.01 | |||
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 28.93 | |||
| Value At Risk | (8.30) | |||
| Potential Upside | 8.55 |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in ACELYRIN, INC Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACELYRIN, INC. If investors know ACELYRIN, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACELYRIN, INC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Return On Assets (0.33) | Return On Equity (0.42) |
The market value of ACELYRIN, INC Common is measured differently than its book value, which is the value of ACELYRIN, that is recorded on the company's balance sheet. Investors also form their own opinion of ACELYRIN, INC's value that differs from its market value or its book value, called intrinsic value, which is ACELYRIN, INC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACELYRIN, INC's market value can be influenced by many factors that don't directly affect ACELYRIN, INC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACELYRIN, INC's value and its price as these two are different measures arrived at by different means. Investors typically determine if ACELYRIN, INC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACELYRIN, INC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.